Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A trial of a new inhaled antiviral drug for COVID-19 has shown positive results and the drug is now moving into a larger international phase 3 trial of hospitalised patients.

Digital illustration of a human with a transparent body and model of coloured lungs inside with coronavirus particle models.

A new treatment, a protein called interferon beta or SNG001, has been developed with results from the phase 2 trial published in the Lancet Respiratory Medicine journal. The study showed that hospitalised COVID-19 patients on nebulised interferon bets recovered quicker and that the drug was safe.

Interferon beta, produced naturally by the body when it gets a viral infection, is inhaled directly into the lungs of patients with coronavirus using a nebuliser, with the aim of reducing viral load and stimulating an immune response. Oxford University Hospitals contributed 10% of the patients in the phase 2 trial.

The large phase 3 trial, which is expected to involve 900 participants and take place in up to 20 NHS sites, has been deemed an urgent public health research study by the Department of Health and Social Care, and will be prioritised for set-up and delivery across the NHS by the NIHR Clinical Research Network over the coming months.

The full story is available on the NIHR Oxford Biomedical Research Centre website

The story is also featured on the MRC Weatherall Institute of Molecular Medicine website

Similar stories

Oxford announces the founding of the new Bennett Institute for Applied Data Science

The Bennett Institute for Applied Data Science at the University of Oxford has been established to pioneer the better use of data, evidence and digital tools in healthcare and policy, optimizing the impact of interventions to achieve improved outcomes.

Researchers develop machine learning algorithm to diagnose deep vein thrombosis

A team of researchers are developing the use of an artificial intelligence (AI) algorithm with the aim of diagnosing deep vein thrombosis (DVT) more quickly and as effectively as traditional radiologist-interpreted diagnostic scans, potentially cutting down long patient waiting lists and avoiding patients unnecessarily receiving drugs to treat DVT when they don’t have it.

COVID-19 recovery project nominated for HSJ award

The project, involving Oxford University Hospitals, Defence Medical Services (DMS), and the Radcliffe Department of Medicine is in the running for a prestigious honour at the Health Service Journal Awards 2021.

Oxford to assess revolutionary multi-cancer blood test in trial, for future implementation in the NHS

A partnership between the University of Oxford and GRAIL, LLC will evaluate the use of a new, non-invasive, multi-cancer early detection test known as Galleri in suspected cancer patients.

'Finding our Way: An NHS Tribute Garden' at RHS Chelsea Flower Show 2021

‘Finding Our Way – An NHS Tribute Garden’ is a celebration of the incredible efforts of the thousands of people who fought – and are still fighting - the COVID-19 pandemic on our behalf. The garden is designed by Naomi Ferrett-Cohen and presented by Oxford University Hospitals NHS Foundation Trust and Oxford University.